Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQH3906 in Systemic Lupus Erythematosus
NCT07509892Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQH3906 in systemic lupus erythematosus (SLE), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jun 2026; status: recruiting.
02
Drugs
TQH3906
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07509892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509892.